{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T20:20:10Z","timestamp":1778703610140,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.bmcl.2022.128680","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T12:56:48Z","timestamp":1647435408000},"page":"128680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Design, synthesis and structure-activity relationship studies of pyrido[2,3-d]pyrimidin-7-ones as potent Janus Kinase 3 (JAK3) covalent inhibitors"],"prefix":"10.1016","volume":"64","author":[{"given":"Wenhong","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingshan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyue","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengchao","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianfeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bmcl.2022.128680_b0005","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci"},{"issue":"4","key":"10.1016\/j.bmcl.2022.128680_b0010","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease","volume":"36","author":"O'Shea","year":"2012","journal-title":"Immunity"},{"issue":"21","key":"10.1016\/j.bmcl.2022.128680_b0015","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/onc.2012.347","article-title":"JAK\/STAT signaling in hematological malignancies","volume":"32","author":"Ferrajoli","year":"2013","journal-title":"Oncogene"},{"issue":"24","key":"10.1016\/j.bmcl.2022.128680_b0020","doi-asserted-by":"crossref","first-page":"8468","DOI":"10.1021\/jm1004286","article-title":"Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection","volume":"53","author":"Flanagan","year":"2010","journal-title":"J Med Chem"},{"issue":"18","key":"10.1016\/j.bmcl.2022.128680_b0025","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1016\/j.bmc.2018.08.005","article-title":"Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor","volume":"26","author":"Hamaguchi","year":"2018","journal-title":"Bioorgan Med Chem"},{"key":"10.1016\/j.bmcl.2022.128680_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112155","article-title":"Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders","volume":"192","author":"Xu","year":"2020","journal-title":"Eur J Med Chem"},{"issue":"4","key":"10.1016\/j.bmcl.2022.128680_b0035","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.berh.2010.02.003","article-title":"Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes","volume":"24","author":"Riese","year":"2010","journal-title":"Best Pract Res Cl Rh"},{"issue":"10","key":"10.1016\/j.bmcl.2022.128680_b0040","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1136\/annrheumdis-2019-215163","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)","volume":"78","author":"Tanaka","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.bmcl.2022.128680_b0045","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"New Engl J Med"},{"issue":"7","key":"10.1016\/j.bmcl.2022.128680_b0050","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.bmcl.2022.128680_b0055","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"10.1016\/j.bmcl.2022.128680_b0060","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.biocel.2009.09.004","article-title":"JAK3: A two-faced player in hematological disorders","volume":"41","author":"Cornejo","year":"2009","journal-title":"Int J Biochem Cell B"},{"issue":"2","key":"10.1016\/j.bmcl.2022.128680_b0065","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/leu.2013.157","article-title":"JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma","volume":"28","author":"Bouchekioua","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.bmcl.2022.128680_b0070","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1038\/leu.2012.74","article-title":"Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia","volume":"26","author":"Bains","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bmcl.2022.128680_b0075","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ccr.2006.06.002","article-title":"Activating alleles of JAK3 in acute megakaryoblastic leukemia","volume":"10","author":"Walters","year":"2006","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.bmcl.2022.128680_b0080","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/s41375-017-0004-x","article-title":"Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer\/T-cell lymphoma","volume":"32","author":"Nairismagi","year":"2018","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.bmcl.2022.128680_b0085","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1016\/j.bmcl.2017.07.079","article-title":"Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting","volume":"27","author":"Forster","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"issue":"16","key":"10.1016\/j.bmcl.2022.128680_b0090","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1021\/acs.jmedchem.5b00710","article-title":"Development of Selective Covalent Janus Kinase 3 Inhibitors","volume":"58","author":"Tan","year":"2015","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.bmcl.2022.128680_b0095","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1021\/acs.jmedchem.6b01694","article-title":"Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-(2S,5R)-5-((7H-Pyrrolo[2,3-d] pyrimidin-4-yl) amino)-2-methylpiperidin-1-y1) prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans","volume":"60","author":"Thorarensen","year":"2017","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.bmcl.2022.128680_b0100","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1021\/acs.jmedchem.8b01823","article-title":"Discovery of an Orally Available Janus Kinase 3 Selective Covalent Inhibitor","volume":"62","author":"Shi","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128680_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112148","article-title":"Design, synthesis, and pharmacological evaluation of 4-or 6-phenyl-pyrimidine derivatives as novel and selective Janus kinase 3 inhibitors","volume":"191","author":"Shu","year":"2020","journal-title":"Eur J Med Chem"},{"issue":"23","key":"10.1016\/j.bmcl.2022.128680_b0110","doi-asserted-by":"crossref","first-page":"10665","DOI":"10.1021\/acs.jmedchem.8b01308","article-title":"Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors","volume":"61","author":"Casimiro-Garcia","year":"2018","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.bmcl.2022.128680_b0115","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.chembiol.2016.10.008","article-title":"Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket","volume":"23","author":"Forster","year":"2016","journal-title":"Cell Chem Biol"},{"issue":"9","key":"10.1016\/j.bmcl.2022.128680_b0120","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1039\/C5MD00208G","article-title":"C5-substituted pyrido[2,3-d] pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFR(T790M) mutant","volume":"6","author":"Xu","year":"2015","journal-title":"Medchemcomm"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22001561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22001561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:44:28Z","timestamp":1760773468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X22001561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":24,"alternative-id":["S0960894X22001561"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128680","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and structure-activity relationship studies of pyrido[2,3-d]pyrimidin-7-ones as potent Janus Kinase 3 (JAK3) covalent inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128680","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128680"}}